TABLE 2.
Summary of recommendations in this guideline
| Therapy | Recommendations | Strength of recommendation | Quality of Evidence |
| Corticosteroids | 1) The panel recommends offering treatment with corticosteroids for patients with COVID-19 requiring oxygen, noninvasive ventilation or invasive mechanical ventilation | Strong | Moderate |
| 2) The panel recommends NOT to offer treatment with corticosteroids for patients with COVID-19 requiring hospitalisation but not requiring supplementary oxygen or ventilatory support | Strong | Moderate | |
| IL-6 receptor antagonist monoclonal antibody | 3) The panel suggests offering IL-6 receptor antagonist monoclonal antibody therapy to hospitalised patients with COVID-19 requiring oxygen or ventilatory support | Conditional | Low |
| 4) The panel suggests NOT to offer IL-6 receptor antagonist monoclonal antibody to patients not requiring supplementary oxygen | Conditional | Low | |
| Hydroxychloroquine | 5) The panel recommends NOT to offer hydroxychloroquine to patients with COVID-19, including hospitalised patients and outpatients | Strong | Moderate |
| Azithromycin | 6) The panel suggests NOT to offer azithromycin to hospitalised patients with COVID-19 in the absence of bacterial infection | Conditional | Very low |
| Azithromycin and hydroxychloroquine | 7) The panel suggests NOT to offer hydroxychloroquine and azithromycin in combination to patients with COVID-19 | Conditional | Moderate |
| Colchicine | 8) The panel suggests NOT to offer colchicine for hospitalised patients with COVID-19 | Conditional | Very Low |
| Lopinavir–ritonavir | 9) The panel recommends NOT to offer lopinavir–ritonavir to hospitalised patients with COVID-19 | Strong | Low |
| Remdesivir | 10) No recommendation is made regarding the use of remdesivir in patients hospitalised with COVID-19 and not requiring invasive mechanical ventilation | None | Moderate |
| 11) The panel suggests not to offer remdesivir to patients hospitalised with COVID-19 infection who require invasive mechanical ventilation | Conditional | Moderate | |
| Interferon-β | 12) The panel suggests NOT to offer interferon-β to hospitalised patients with COVID-19 | Conditional | Very low |
| Anticoagulation | 13) The panel recommends offering a form of anticoagulation to hospitalised patients with COVID-19 | Strong | Very low |
| Noninvasive ventilatory support | 14) We suggest HFNC or noninvasive CPAP delivered through either a helmet or a facemask for patients with COVID-19 and hypoxaemic acute respiratory failure without an immediate indication for invasive mechanical ventilation | Conditional | Very low |
In the document, high-flow nasal cannula oxygen therapy (HFNC) is integrated in the term “noninvasive ventilatory support”. IL: interleukin; COVID-19: coronavirus disease 2019; CPAP: continuous positive airway pressure.